BRPI0517100A - composto ou um sal farmaceuticamente aceitável do mesmo, método para preparar um composto, composição farmacêutica, e, métodos para tratar um paciente sofrendo de distúrbios e de deficiência - Google Patents

composto ou um sal farmaceuticamente aceitável do mesmo, método para preparar um composto, composição farmacêutica, e, métodos para tratar um paciente sofrendo de distúrbios e de deficiência

Info

Publication number
BRPI0517100A
BRPI0517100A BRPI0517100-8A BRPI0517100A BRPI0517100A BR PI0517100 A BRPI0517100 A BR PI0517100A BR PI0517100 A BRPI0517100 A BR PI0517100A BR PI0517100 A BRPI0517100 A BR PI0517100A
Authority
BR
Brazil
Prior art keywords
compound
methods
treating
preparing
pharmaceutically acceptable
Prior art date
Application number
BRPI0517100-8A
Other languages
English (en)
Inventor
Alvin C Bach
Sivaramakrishnan P Ramamoorthy
Zenn Tong
Jim Wang
William Demaio
Ronald A Jordan
Gary P Stack
Youchu Wang
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0517100A publication Critical patent/BRPI0517100A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/22—Pteridine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)

Abstract

COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, MéTODO PARA PREPARAR UM COMPOSTO, COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA TRATAR UM PACIENTE SOFRENDO DE DISTúRBIOS E DE DEFICIêNCIA. A invenção diz respeito a metabólitos de certos derivados de ¢í,4!diazapino-¢6,7,1-ij!quinolina e métodos de preparação e seu uso. Especificamente, a invenção diz respeito a compostos de fórmula 1 em que os vários substituintes são definidos neste relatório descritivo. A invenção também fornece composições farmacêuticas que incluem compostos de fórmula 1, métodos de produzir tais compostos, e métodos de usar tais compostos.
BRPI0517100-8A 2004-11-05 2005-11-04 composto ou um sal farmaceuticamente aceitável do mesmo, método para preparar um composto, composição farmacêutica, e, métodos para tratar um paciente sofrendo de distúrbios e de deficiência BRPI0517100A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62533504P 2004-11-05 2004-11-05
PCT/US2005/040289 WO2006052886A1 (en) 2004-11-05 2005-11-04 Metabolites of certain [1,4]diazepino[6,7,1-ij]quinoline derivatives and methods of preparation and use thereof

Publications (1)

Publication Number Publication Date
BRPI0517100A true BRPI0517100A (pt) 2008-09-30

Family

ID=36002462

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517100-8A BRPI0517100A (pt) 2004-11-05 2005-11-04 composto ou um sal farmaceuticamente aceitável do mesmo, método para preparar um composto, composição farmacêutica, e, métodos para tratar um paciente sofrendo de distúrbios e de deficiência

Country Status (18)

Country Link
US (1) US20060111305A1 (pt)
EP (1) EP1812436A1 (pt)
JP (1) JP2008519056A (pt)
KR (1) KR20070084009A (pt)
CN (1) CN101124225A (pt)
AR (1) AR052227A1 (pt)
AU (1) AU2005304757A1 (pt)
BR (1) BRPI0517100A (pt)
CA (1) CA2586122A1 (pt)
CR (1) CR9092A (pt)
GT (1) GT200500319A (pt)
IL (1) IL182755A0 (pt)
MX (1) MX2007005475A (pt)
NO (1) NO20072165L (pt)
PE (1) PE20060939A1 (pt)
RU (1) RU2007116264A (pt)
TW (1) TW200635926A (pt)
WO (1) WO2006052886A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
TW200806300A (en) * 2006-03-24 2008-02-01 Wyeth Corp New therapeutic combinations for the treatment of depression
PE20081192A1 (es) * 2006-03-24 2008-10-07 Wyeth Corp Tratamiento del dolor
AU2007229491A1 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN111303218B (zh) * 2020-03-17 2021-03-30 连江仁泽生物科技有限公司 一种马鞭草苷的合成方法及应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3158619A (en) * 1962-06-14 1964-11-24 Searle & Co Certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3235564A (en) * 1964-03-27 1966-02-15 Searle & Co Intermediates to certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3335134A (en) * 1964-04-02 1967-08-08 Sandoz Ag Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones
US3296252A (en) * 1964-04-02 1967-01-03 Sandoz Ag Tetracyclic diazepinone compounds
GB1120462A (en) * 1964-07-06 1968-07-17 Manuf Prod Pharma 3-alkoxy-2h-fluoreno[1,9-ef]-1,4-diazepine 1-oxides and derivatives thereof
US3417101A (en) * 1964-11-09 1968-12-17 American Home Prod Fused ring compounds
US3329676A (en) * 1964-11-09 1967-07-04 American Home Prod Fused 1, 4-diazepine ring systems
US3714149A (en) * 1969-11-03 1973-01-30 Upjohn Co Pyridobenzodiazepinones
US3914250A (en) * 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US4880814A (en) * 1987-11-13 1989-11-14 Abbott Laboratories 7-cycloalkyl naphthyridines
GB8812636D0 (en) * 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
EP0357417A1 (en) * 1988-09-01 1990-03-07 Glaxo Group Limited Lactam derivatives
ES2067744T3 (es) * 1989-06-09 1995-04-01 Upjohn Co Aminas heterociclicas con actividad sobre el sistema nervioso central.
NZ314105A (en) * 1996-02-02 1997-12-19 Sumitomo Pharma Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring
US6380166B1 (en) * 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
US6761904B2 (en) * 2000-03-31 2004-07-13 Nycomed Austria Gmbh Pharmaceutical kit comprising midodrine as active drug substance
US6503900B2 (en) * 2000-11-03 2003-01-07 Wyeth [1,4]diazepino [6,7,1-jk ]carbazoles and derivatives
US6916922B2 (en) * 2000-11-03 2005-07-12 Wyeth Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives
AR031197A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta(b) diazepino(6,7,1-hi)indol
US6777407B2 (en) * 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6414144B1 (en) * 2000-11-03 2002-07-02 Wyeth Process for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi] indole derivatives
AR031199A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
AR031196A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de ciclopenta (b) (1,4)-diazepino (6,7,1-hi) indoles y derivados
US6759405B2 (en) * 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
MXPA03005438A (es) * 2000-12-20 2004-05-05 Bristol Myers Squibb Co Pirioindoles substituidos como agonistas y antagonistas de serotonina.
JP2005501092A (ja) * 2001-08-06 2005-01-13 ファルマシア・アンド・アップジョン・カンパニー 治療上有用な四環リガンド
TWI312781B (en) * 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) * 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TW200307682A (en) * 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
AU2003303210A1 (en) * 2002-12-19 2004-07-14 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
AU2007229491A1 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders

Also Published As

Publication number Publication date
EP1812436A1 (en) 2007-08-01
US20060111305A1 (en) 2006-05-25
TW200635926A (en) 2006-10-16
NO20072165L (no) 2007-07-25
CR9092A (es) 2007-10-23
GT200500319A (es) 2006-06-02
IL182755A0 (en) 2007-07-24
MX2007005475A (es) 2007-05-24
AR052227A1 (es) 2007-03-07
KR20070084009A (ko) 2007-08-24
CN101124225A (zh) 2008-02-13
AU2005304757A1 (en) 2006-05-18
JP2008519056A (ja) 2008-06-05
WO2006052886A1 (en) 2006-05-18
PE20060939A1 (es) 2006-11-10
CA2586122A1 (en) 2006-05-18
RU2007116264A (ru) 2008-12-10
WO2006052886A8 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
MX2022000854A (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr.
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
TW200621762A (en) Novel compounds
EA200700099A1 (ru) Производные пиридина
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
TW200510297A (en) Substituted n-aryl heterocycles, process for their preparation and their use as medicaments
DE60140814D1 (de) N-phenyl-2-pyrimidine-amine derivatives
BRPI0317717B8 (pt) composto, composição farmacêutica, e uso de um composto
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
BRPI0416212A (pt) derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
BRPI0514537B8 (pt) compostos de aminoeteroarila substituídos com pirazol e composição farmacêutica que os compreende
NO20062139L (no) Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister
BRPI0418351A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0607796A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
TW200508207A (en) New benzimidazole derivatives
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2210 DE 14/05/2013.